Treace Medical Concepts
Treace Medical Concepts' revenue rose 1.6% to $213 million in fiscal 2025. Its operating margin was −25.5%, up from −26.6% a year earlier. Free cash flow was −$29 million. The diluted share count rose 1.9%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
Income statement
Treace Medical Concepts lost money in fiscal 2025: a net loss of $59 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 106 | 81 | 123 | 76 | 48 |
| Debt incl. finance leases | 29 | 53 | 53 | 53 | 57 |
| Net debt (negative means net cash) | −76 | −29 | −70 | −22 | 9 |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | 0.3x | 0.9x | 0.4x | 0.5x | 0.7x |
| Interest coverage | −4.1x | −7.9x | −9.9x | −10.6x | −10.2x |
| Current ratio | 7.6x | 4.4x | 4.4x | 4.6x | 4.3x |
| Quick ratio | 7.0x | 3.8x | 3.8x | 3.5x | 3.1x |
Cash flow
Projections
Project Treace Medical Concepts' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 1 insider bought $1.4 million of Treace Medical Concepts shares on the open market, and none sold any.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Aug 24, 2026 | John T. TreaceChief Executive Officer, Director, 10% owner | Bought | 11,000 | $4.34 | $47,740 | Form 4 |
| Aug 21, 2026 | John T. TreaceChief Executive Officer, Director, 10% owner | Bought | 5,000 | $4.35 | $21,750 | Form 4 |
| Aug 20, 2026 | John T. TreaceChief Executive Officer, Director, 10% owner | Bought | 39,944 | $4.44 | $177,351 | Form 4 |
| Jun 11, 2026 | John T. TreaceChief Executive Officer, Director, 10% owner | Bought | 22,887 | $4.04 | $92,463 | Form 4 |
| Jun 10, 2026 | John T. TreaceChief Executive Officer, Director, 10% owner | Bought | 29,430 | $4.02 | $118,309 | Form 4 |
| Jun 1, 2026 | John T. TreaceChief Executive Officer, Director, 10% owner | Bought | 50,000 | $3.56 | $178,000 | Form 4 |
| May 28, 2026 | John T. TreaceChief Executive Officer, Director, 10% owner | Bought | 61,202 | $3.02 | $184,830 | Form 4 |
| May 27, 2026 | John T. TreaceChief Executive Officer, Director, 10% owner | Bought | 49,810 | $2.87 | $142,955 | Form 4 |
| May 26, 2026 | John T. TreaceChief Executive Officer, Director, 10% owner | Bought | 4,508 | $2.79 | $12,577 | Form 4 |
| May 14, 2026 | John T. TreaceChief Executive Officer, Director, 10% owner | Bought | 61,750 | $2.62 | $161,785 | Form 4 |
| May 13, 2026 | John T. TreaceChief Executive Officer, Director, 10% owner | Bought | 49,013 | $2.46 | $120,572 | Form 4 |
| May 12, 2026 | John T. TreaceChief Executive Officer, Director, 10% owner | Bought | 43,000 | $2.17 | $93,310 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 3 of 9 | 4 of 9 | 2 of 9 |
| Rule of 40 | 7.3% | −11.4% | −12.3% |
| Altman Z'' | 2.15 | 0.38 | −1.79 |
| Accruals ratio | −7.3% | −7.9% | −21.1% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Fail | Pass | Fail |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Pass | Pass | Fail |
| Current ratio rose | Fail | Pass | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Fail | Fail | Fail |
| Revenue rose relative to assets | Pass | Fail | Pass |
| F-score | 3 of 9 | 4 of 9 | 2 of 9 |
Compare
Put Treace Medical Concepts side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Treace Medical Concepts | FY25 | 1.6% | −25.5% | −13.9% | −45.8% | — | 2 | |
| Establishment Labs Holdings | FY25 | 27.1% | −18.5% | −27.0% | −39.0% | — | 3 | Compare |
| SI-BONE | FY25 | 20.2% | −11.1% | −4.5% | −26.3% | — | 6 | Compare |
| Axogen | FY25 | 20.2% | −3.5% | −1.3% | −4.9% | — | 5 | Compare |
| Cerus | FY25 | 16.1% | −3.7% | 0.5% | — | — | — | Compare |
7 years of figures
| Fiscal year | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 39 | 57 | 94 | 142 | 187 | 209 | 213 |
| Revenue growth | — | 45.5% | 64.6% | 50.2% | 31.9% | 11.9% | 1.6% |
| Gross profit | 32 | 45 | 78 | 116 | 152 | 168 | 170 |
| Research and development | 5 | 6 | 10 | 14 | 15 | 21 | 20 |
| Operating income | −4 | 1 | −16 | −35 | −51 | −56 | −54 |
| Net income | −4 | −4 | −21 | −43 | −50 | −56 | −59 |
| Diluted EPS (US$) | −0.13 | −0.12 | −0.43 | −0.77 | −0.81 | −0.90 | −0.93 |
| Diluted shares (millions) | 37 | 37 | 48 | 55 | 61 | 62 | 63 |
| Cash flow | |||||||
| Cash from operations | −8 | −4 | −17 | −31 | −35 | −37 | −16 |
| Capital expenditure | 1 | 1 | 3 | 15 | 12 | 12 | 14 |
| Free cash flow | −9 | −6 | −20 | −45 | −46 | −49 | −29 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 20 | 0 | 0 |
| Stock-based compensation | 1 | 1 | 3 | 8 | 17 | 31 | 34 |
| Balance sheet at fiscal year end | |||||||
| Cash and short-term investments | 12 | 18 | 106 | 81 | 123 | 76 | 48 |
| Debt incl. finance leases | — | 31 | 29 | 53 | 53 | 53 | 57 |
| Total assets | — | 42 | 141 | 159 | 252 | 217 | 191 |
| Total liabilities | — | 41 | 48 | 98 | 114 | 104 | 103 |
| Shareholders' equity | 3 | 1 | 93 | 60 | 138 | 113 | 87 |
| Margins and ratios | |||||||
| Gross margin | 80.6% | 78.3% | 82.1% | 82.0% | 81.2% | 80.4% | 79.8% |
| Operating margin | −9.0% | 1.5% | −17.5% | −24.6% | −27.5% | −26.6% | −25.5% |
| Net margin | −10.8% | −6.4% | −21.8% | −30.2% | −26.5% | −26.6% | −27.7% |
| Free cash flow margin | −22.5% | −9.7% | −21.1% | −32.1% | −24.6% | −23.3% | −13.9% |
| Rule of 40 (growth + FCF margin) | — | 35.8% | 43.5% | 18.1% | 7.3% | −11.4% | −12.3% |
| Return on capital | — | — | −86.2% | −113.3% | −81.5% | −55.6% | −45.8% |
| Return on equity | — | — | −43.8% | −55.8% | −49.9% | −44.5% | −58.9% |
| Return on assets | — | — | −22.5% | −28.6% | −24.1% | −23.8% | −28.9% |
| Net debt to EBITDA | — | 6.2x | — | — | — | — | — |